Non-viral nanovectors for gene delivery: factors that govern successful therapeutics

被引:44
作者
Viola, Joana R. [1 ]
El-Andaloussi, Samir [1 ]
Oprea, Iulian I. [1 ]
Smith, C. I. Edvard [1 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp Huddinge, Clin Res Ctr, Dept Lab Med, S-14157 Huddinge, Sweden
基金
瑞典研究理事会;
关键词
in vivo; intravenous administration; nanoparticles; receptor-mediated uptake; PLURONIC BLOCK-COPOLYMERS; CELL-PENETRATING PEPTIDES; LIPID-LIKE MATERIALS; IN-VIVO; TRANSGENE EXPRESSION; TARGETED DELIVERY; SKELETAL-MUSCLE; SIRNA DELIVERY; PLASMID DNA; NANOPARTICLES;
D O I
10.1517/17425241003716810
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Gene therapy is regarded as one of the most promising therapeutic approaches, as it has the potential to treat disorders by correcting malformations at the nucleic acids. Areas covered in this review: Some of the most recent developments in the process of plasmid DNA vector design and formulation are reviewed with a special focus on: different formulations of nanovectors and a summary of successful cases reported; requirements for systemic administration; and functionalization of the nanocarriers by use of targeting entities. What the reader will gain: An understanding of the different physiological barriers and a comprehensive review of the recent strategies used to overcome these obstacles. Particular attention is given to formulations for intravenous administration, colloidal stability properties and different targeting entities used. Take home message: Overall, vector formulation must take into account the administration route and inherent physiological barriers. Critical parameters for the success of pDNA nanovectors are: particles size, colloidal stability of the formulation and interaction between the carrier and plasmid DNA. Highly relevant is the fact that this interaction should be balanced to offer protection to degradation as well as allow dissociation of the therapeutic nucleic acid for obtaining maximal activity.
引用
收藏
页码:721 / 735
页数:15
相关论文
共 135 条
  • [1] A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
    Akinc, Akin
    Zumbuehl, Andreas
    Goldberg, Michael
    Leshchiner, Elizaveta S.
    Busini, Valentina
    Hossain, Naushad
    Bacallado, Sergio A.
    Nguyen, David N.
    Fuller, Jason
    Alvarez, Rene
    Borodovsky, Anna
    Borland, Todd
    Constien, Rainer
    de Fougerolles, Antonin
    Dorkin, J. Robert
    Jayaprakash, K. Narayanannair
    Jayaraman, Muthusamy
    John, Matthias
    Koteliansky, Victor
    Manoharan, Muthiah
    Nechev, Lubomir
    Qin, June
    Racie, Timothy
    Raitcheva, Denitza
    Rajeev, Kallanthottathil G.
    Sah, Dinah W. Y.
    Soutschek, Juergen
    Toudjarska, Ivanka
    Vornlocher, Hans-Peter
    Zimmermann, Tracy S.
    Langer, Robert
    Anderson, Daniel G.
    [J]. NATURE BIOTECHNOLOGY, 2008, 26 (05) : 561 - 569
  • [2] Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver
    Akinc, Akin
    Goldberg, Michael
    Qin, June
    Dorkin, J. Robert
    Gamba-Vitalo, Christina
    Maier, Martin
    Jayaprakash, K. Narayanannair
    Jayaraman, Muthusamy
    Rajeev, Kallanthottathil G.
    Manoharan, Muthiah
    Koteliansky, Victor
    Roehl, Ingo
    Leshchiner, Elizaveta S.
    Langer, Robert
    Anderson, Daniel G.
    [J]. MOLECULAR THERAPY, 2009, 17 (05) : 872 - 879
  • [3] Akita H, 2008, EXPERT OPIN DRUG DEL, V5, P847, DOI [10.1517/17425247.5.8.847, 10.1517/17425247.5.8.847 ]
  • [4] Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer
    Alakhov, VY
    Moskaleva, EY
    Batrakova, EV
    Kabanov, AV
    [J]. BIOCONJUGATE CHEMISTRY, 1996, 7 (02) : 209 - 216
  • [5] Alexander JH, 2005, JAMA-J AM MED ASSOC, V294, P2446
  • [6] Factors affecting the clearance and biodistribution of polymeric nanoparticles
    Alexis, Frank
    Pridgen, Eric
    Molnar, Linda K.
    Farokhzad, Omid C.
    [J]. MOLECULAR PHARMACEUTICS, 2008, 5 (04) : 505 - 515
  • [7] Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with Neovascular age-related macular degeneration
    Apte, Rajendra S.
    [J]. OPHTHALMOLOGY, 2007, 114 (09) : 1702 - 1712
  • [8] Increased receptor-mediated gene delivery to the liver by protamine-enhanced-asialofetuin-lipoplexes
    Arangoa, MA
    Düzgünes, N
    de Ilarduya, CT
    [J]. GENE THERAPY, 2003, 10 (01) : 5 - 14
  • [9] Avgoustakis Konstantinos, 2004, Current Drug Delivery, V1, P321, DOI 10.2174/1567201043334605
  • [10] Physicochemical Parameters of Non-Viral Vectors that Govern Transfection Efficiency
    Barteau, Benoit
    Chevre, Raphael
    Letrou-Bonneval, Emilie
    Labas, Romain
    Lambert, Olivier
    Pitard, Bruno
    [J]. CURRENT GENE THERAPY, 2008, 8 (05) : 313 - 323